Pediatric health: mechanistic insights into inflammatory diseases and emerging therapeutic pathway-targeted approaches

Introduction

Pediatric inflammatory diseases are increasing globally and represent a new health burden on society with severe consequences for childhood health and development. Infectious diseases such as inflammatory bowel disease (IBD), atopic dermatitis (AD), Kawasaki disease (KD), and multisystem inflammatory syndrome (MIS) have increased in prevalence over the past decade and represent a significant strain on health systems. Pediatric inflammatory diseases of the immune system involve improper activations leading to chronic inflammatory management with implications extending beyond childhood if not properly managed (1).

The determinants of early immune dysregulation are strong antecedents to long-term health trajectories in pediatric inflammatory diseases. The immune system in children is still maturing through environmental exposures and genetic predispositions that can trigger or enhance inflammatory disease processes. Early immune stability can be disrupted, leading to acute manifestations that can present as chronic complications for pediatric patients (i.e., autoimmunity, deformities, cognitive decline). Understanding how early immune responses function is critical to advancing our diagnostic and treatment approaches (2).

Most previous research on pediatric inflammatory diseases has focused on describing the pathology associated with visible injuries along the disease’s path. While working to understand the molecular pathway mechanisms of inflammation, we will identify possible mechanisms via potential therapeutic targets. Mechanistic studies have the ability to lead to better personalized therapeutic approaches that will lessen the symptoms and correct the immune system dysfunctions that perpetuate these diseases (3).

The ultimate goal of this review is to evaluate mechanistic studies of pediatric inflammatory diseases and explore the different pathways and processes that are being engaged. With an emphasis on multisystem inflammatory syndrome in children (MIS-C), a recently identified post-viral illness, this study explores how immune ontogeny affects both acute and chronic inflammatory disorders in children. While chronic inflammatory conditions, including asthma and IBD, are well-established, MIS-C offers a special and opportune chance to investigate acute immune responses in the juvenile population. This review offers a fresh, thorough, and clinically relevant synthesis of juvenile inflammatory disease by combining developmental immunology, molecular pathways, translational therapies, and pediatric-specific safety issues. We also highlight cutting-edge developments that set this review apart from traditional summaries, such as JAK inhibitors, gene editing, microbiome treatments, and multi-omics-guided precision medicine. A hyperinflammatory reaction after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (viral illness caused by the novel coronavirus that emerged in 2019, leading to COVID-19 and associated inflammatory complications in children) is the hallmark of MIS-C, providing insight into how children’s developing immune systems may overreact to viral infections. This study shows how immune ontogeny shapes unique inflammatory pathways and how the immune system’s development affects disease progression, responses to infections, and therapeutic approaches, examining both acute and chronic illnesses (4,5). Research on pediatric inflammatory illnesses, including asthma, IBD, and juvenile idiopathic arthritis (JIA), has long been conducted. Recent discoveries, however, have provided a new understanding of these illnesses by identifying new mechanisms that lead to immunological dysregulation in children. This review focuses on age-specific molecular variations that increase the pediatric immune system’s vulnerability to autoimmune reactions and chronic inflammation. We also discuss the most recent treatment developments, such as JAK inhibitors, gene-editing technologies, and microbiome-based interventions, which mark a substantial change in pediatric precision medicine. Additionally, the incorporation of omics-driven insights, such as proteomics, metabolomics, and genomics, offers intriguing paths for individualized treatment plans (6).

Compared to traditional reviews that delve into pediatric inflammatory diseases (e.g., JIA, IBD, asthma separately), we adopt a mechanism-first approach, organizing content around common molecular pathways (cytokine signaling, inflammasome activation, oxidative stress, gut-immune axis) that permeate multiple pediatric inflammatory conditions. Such a cross-cutting structure allows for highlighting common therapeutic targets and facilitates the translation of insights from one disease to another. Further setting this review apart is our strong focus on ontogeny—how the developing pediatric immune system diverges in significant ways from adult immunity—which we use to inform our mechanistic and therapeutic discussions throughout. Finally, we also bring to bear emerging multi-omics technologies (genomics, proteomics, metabolomics) plus AI-driven pathway analysis and precision approaches, offering a forward-looking perspective that is rarely embedded within traditional pediatric inflammation reviews. In blending developmental immunology, molecular mechanisms, and translational therapeutics, this review aims to be a powerhouse resource for both researchers and clinicians.

Pediatric inflammation: a unique landscape

Key considerations for clinical immunology regarding pediatric inflammatory diseases are that the developing immune system of children has its own unique characteristics, more than just differences of maturity and immune plasticity. The immune ontogeny in children is fundamentally different from that in adults, and this is particularly true in early life when the immune system is developing. During infancy and early childhood, T and B lymphocytes develop rapidly, along with attendant immune maturation. This rapid cell development and signaling provide the pediatrician with the ability to develop levels of immune response, but, as a necessary consequence, it leads to a higher susceptibility to inflammatory diseases. By way of example, a child’s immune system is not fully ‘trained’ to respond to inflammatory signals, particularly signals that present as “bad things to fight” and “nice/normal cell clusters” (7).

On the other side of immune ontogeny, plasticity means the developing and maturing child typically has a more robust immune response to surrounding joint environmental challenges. In being flexible, the child can adapt to and fight infections and new antigens quickly; however, this also means the pediatric immune system is more susceptible to misdirection in response to stimuli, leading to chronic inflammatory responses and/or autoimmune conditions. Therefore, adult immune responses to pathogens are often more stable and regulated, whereas children are often more flexible and therefore less regulated in response to prior insults and their unique genetic predispositions (8).

An important factor in pediatric inflammation is immune imprinting, the long-term effects of early-life immune experiences on immune system development, including tolerance and regulation. Early-life “developmental windows” are essential for establishing immune tolerance and regulation. Whatever disrupts normal immune function during those windows—infections (irrespective of severity), dysregulation of the immune system, or exposures to environmental factors—has the potential to permanently alter immune function, thus increasing susceptibility to inflammatory diseases later in life. For instance, disruption of immune tolerance in early childhood could lead to an autoimmune condition such as JIA or asthma (9). Figure 1 shows children’s immune systems are constantly developing, and hematopoietic stem cells (HSCs) are essential for the production of blood cells throughout life. Both adults and children have HSCs, which guarantee the ongoing synthesis of immune cells required for immunological function and regeneration. Children’s immune systems are still developing, and to mount immune responses, HSCs rapidly differentiate into distinct immune cells, including T and B lymphocytes. Adults, on the other hand, have a more fixed and less flexible immune function but maintain HSCs for immune system replenishment (10). These fundamental differences in immune ontogeny and developmental windows, discussed above, have direct implications for disease mechanisms (section Key mechanistic pathways in pediatric inflammation and section Dysregulated neutrophil and macrophage activation in children) and therapeutic approaches (section Therapeutic approaches targeting pathways), as will be highlighted throughout this review.

Figure 1 Development of the immune system in adults and children. The function of HSCs in both adults and children is depicted in this image. HSCs rapidly differentiate into immune cells in early life, helping the immune system become more adaptable. Children’s immune systems develop as they age, but they remain highly responsive to infections and environmental exposures. Adults, on the other hand, have a less adaptive and more controlled immune system because they maintain a steady level of HSC activity and replace immune cells more slowly. The image highlights that whereas HSCs, which are necessary for immune function throughout life, are present in both children and adults, the rates of immune development and plasticity vary across these life stages. HSCs, hematopoietic stem cells.

Key mechanistic pathways in pediatric inflammation

Innate immune activation

The innate immune system serves a critical function for all animals in recognising, responding to, and defending against pathogens while regulating the inflammatory response. It is activated upon recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The latter are widely detected by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and inflammasomes. These primary immune responses are critical during the pathogenesis of many pediatric inflammatory conditions, and misregulated innate immune activation can lead to chronic inflammation, tissue injury, and long-term sequelae in affected children (11). A feature of the innate immune function of the host and microbiome that is different in the adult and pediatric immune system is that in the adult, almost everything related to innate immune responses, has a much more potent response to PRRs, such as TLRs aberrantly recognizes PAMPs. However, in neonates and infants, TLRs elicit a much less potent production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6, but produce more IL-10 responses to restrain excessive inflammatory responses during the early microbial colonization process. Hypo-responsiveness impacts pathogen clearance in a way that prolonged pathogen persistence increases chronic inflammation if challenge occurs. Neutrophils from neonates exhibit a decreased capacity for chemotaxis and impaired phagocytosis, putting them at risk of infection and the possibility of triggering that inflammatory cascade. Adult innate immune cells are better suited to quickly responding to infection but may also be less adaptable and plastic in their responses (and amenable to reprogramming) (12).

TLRs

TLRs are PRRs that are vital for initiating the innate immune response to recognise PAMPs found in microbial components (e.g., lipopolysaccharides, bacterial DNA, and viral RNA) and DAMPs released from damaged tissue. TLRs are located on the surface of multiple immune cell types (e.g., macrophages, dendritic cells, and neutrophils), and when TLRs recognize these unique molecular patterns, they activate intracellular signaling pathways that induce the production of pro-inflammatory mediators (e.g., IL-1β, TNF-α, and IL-6) that mediate the acute inflammatory response (13).

The varied roles of TLRs in children depend on the developmental stage of the immune system, leading to immunological responses that differ from those in adults. The added immune plasticity of a pediatric immune system makes children susceptible to both sides of TLR signaling being overactive or underactive, which leads to inflammatory disease. For example, excessive TLR activation in the gastrointestinal (GI) tract leads to chronic inflammation and mucosal injury in pediatric IBD. Overactivation of airway TLR4 leads to hyper-responsiveness to environmental stimuli (e.g., allergens) and airway inflammation in asthma (14). Figure 2 shows that the activation in juvenile inflammatory illnesses involves PRRs like TLRs and NLRs, identifying pathogens and damage signals.

Figure 2 The main mechanisms of innate immune activation in pediatric inflammatory diseases. TLRs and inflammasomes (including NLRP3), which are essential for detecting pathogens and stress signals, are the main pathways of innate immune activation in juvenile inflammatory disorders. Pro-inflammatory cytokines, including IL-1 and IL-6, are secreted as a result of this activation. Knowing these processes is especially important for disorders like pediatric IBD and Kawasaki disease, where innate immune dysregulation may play a key role in the onset and progression of pathologies. IBD, inflammatory bowel disease; IL, interleukin; TLRs, Toll-like receptors.

Inflammasomes and NLRP3

Inflammasomes are intracellular protein complexes that act as cellular stress and damage sensors. When activated, they go on to activate caspase-1, which is responsible for processing pro-inflammatory cytokines such as IL-1β and IL-18, which may mediate and exacerbate the inflammatory response. The NLRP3 inflammasome has attracted considerable attention in pediatric inflammatory diseases. The NLRP3 inflammasome can be activated by various stimuli, including infection, metabolic conditions, and cellular stress. When activated, NLRP3 can also modulate pyroptosis, which is a form of programmed cell death that is relevant because it contributes to the release of inflammatory cytokines and tissue damage (15).

When NLRP3 is activated via a causal pathway that is either deliberately or inadvertently altered or dysregulated in pediatric disease, where none are supposed to cause chronic inflammation, it can lead to excessive inflammation. For example, KD, an entity seen in children that can result in vasculitis, is thought to reflect excessive NLRP3 inflammasome activity, as some evidence suggests this is happening in vascular endothelial cells. Further, the aforementioned inflammation of blood vessels and potential damage to coronary arteries may occur via excessive NLRP3 inflammasome activity. Concerning pediatric IBD, the evidence suggests pro-inflammatory dysregulated NLRP3 activation in the intestinal mucosa, which correlates with chronic inflammation and results in further gut damage (16).

Dysregulated neutrophil and macrophage activation in children

Pediatric cytokine imbalance

Cytokines are necessary for regulating immune responses by facilitating communication between immune cells. Cytokines are important in initiating and resolving inflammatory processes. In pediatric inflammatory disease, there are specific cytokines (IL-1, IL-6, TNF-α, and IL-17) that are masters of the immune response, and dysregulation of these cytokines can contribute to the pathogenesis of the disease process. Dysregulation of specific cytokines (IL-1, IL-6, TNF-α, and IL-17) can initiate individual and complicated signaling cascades that immune and inflammatory cells will express to facilitate inflammation, while dysregulation can result in the perpetuation of inflammation and tissue injury. Describing concepts in pediatric inflammatory diseases is important for the development of targeted therapies that aim to reduce dysregulation of these pathways (17).

IL-1—specifically IL-1β is a potent pro-inflammatory cytokine, which plays a critical role in the initiation, propagation, and perpetuation of the inflammatory response. IL-1β binds to its receptor after being activated and will activate associated signaling pathways, such as NF-κB and MAPK, that promote the production of other pro-inflammatory cytokines. In acute pediatric inflammatory disease, dysregulated IL-1β signaling can lead to chronic inflammation with tissue injury. For example, in pediatric IBD, raised levels of IL-1b contribute to chronic intestinal mucosal inflammation and tissue injury. In (KD, which is mainly an angiitis with participation by inflammation of the vessels, driven by excessive activation of IL-1b, vasculitis, and an associated risk of injury to the coronary arteries will develop (18).

IL-6 is an essential cytokine in the regulation of immune responses. IL-6 has previously been highlighted for its role in the acute-phase response. Importantly, IL-6 regulates B cell differentiation, T cell activation, and the production of acute-phase proteins. IL-6 primarily plays a role in signaling that helps transition the acute inflammatory response to a chronic inflammatory state, making it a significant contributor to pediatric inflammatory disease. In pediatric MIS-C, a systemic inflammatory response initiated by a hyper-inflammatory response to the COVID-19 virus caused by SARS-CoV-2; high levels of IL-6 are observed, which contribute to a cytokine storm and changes observed from involvement in other organ systems (19). Pediatric cytokine milieu. Children have a different cytokine milieu, both quantitatively and qualitatively, than adults. Small children tend to have higher baseline IL-6 and IL-1β levels but more rapid resolution with treatment of inflammatory diseases than adults. This is likely due to the greater plasticity of the developing immune system. For example, in IBD, mucosal TNF-α relates to severity in children as in adults, but children tend to have greater Th17 cells and to respond better to anti-TNF in a way that is age dependent. In adults, the cytokine manifestation tends to be more fixed and harder to reverse. Thus, children’s inflammatory diseases are not “smaller cut” versions of adults—they appear to have different pathophysiology. In pediatric patients, not recognizing these biological differences may result in abandoning the pediatric patients with these inflammatory diseases because of the concept that adult protocols would work in smaller, younger versions of themselves (20).

TNF-α is a pro-inflammatory cytokine that is central to both the regulation of the immune response and the pathogenesis of many inflammatory diseases. It is produced by activated macrophages, dendritic cells, and T cells, and it exerts immune-mediated effects by activating TNF receptors, which trigger additional signaling through pathways such as NF-κB. In pediatric JIA, TNF-α is upregulated, contributing to ongoing joint inflammation, pain, and damage (21).

Likewise, in pediatric IBD, overproduction of TNF-α from the intestinal mucosa was associated with chronic intestinal inflammation and ulceration. Anti-TNF therapies such as infliximab and adalimumab have been widely used to manage IBD, underscoring TNF-α as a drug target (22). Interleukin-17 (IL-17) is another cytokine that regulates the immune process and plays a role in autoimmune and inflammatory diseases. In pediatric IBD, IL-17 production in the intestinal mucosa is associated with the persistence of inflammation and disease progression. Therapies that target IL-17, such as secukinumab, are being tested for the treatment of IBD to downregulate inflammation by decreasing the mediation and stimulus of the immune response (23).

One interesting difference among the cytokine profiles between pediatric and adult inflammatory diseases is the nature of the immune response in children. To illustrate, in pediatric KD, the cytokine profile includes elevated concentrations of IL-6, TNF-α, and IL-1, which drive systemic inflammation and vascular damage. In adult diseases such as rheumatoid arthritis, there exists a prolonged inflammatory response and a higher concentration of IL-6 and TNF-α, but different disease progression. The large variation in cytokine profiles in pediatric diseases illustrates the need for pediatric-specific therapeutic approaches. Children’s immune systems function differently from adults, and therefore, cytokine-led therapies do likely also include pediatric tailored approaches that would require attention in order to achieve successful therapeutic benefits (24). Figure 3 provides an overview of the major cytokine signaling pathways in pediatric inflammation, highlighting how IL-1, IL-6, TNF-α, and IL-17 activate NF-κB and JAK/STAT pathways to drive inflammation and tissue damage in diseases such as asthma, IBD, and JIA.

Figure 3 Gives a diagrammatic representation of the major cytokine signaling pathways involved in pediatric inflammation. It demonstrates how IL-1, IL-6, TNF-α, and IL-17 can interact with the NF-κB, JAK/STAT, or other pathways to promote and exacerbate inflammation and tissue injury. The diagram understanding the role of cytokine dysregulation and its contribution to conditions such as asthma, IBD, and JIA. IBD, inflammatory bowel disease; IL, interleukin; JIA, juvenile idiopathic arthritis; TNF-α, tumor necrosis factor-alpha.

Adaptive immune dysregulation

Appropriate immune responses depend on the balance of Th1, Th2, and Th17 cells. Th2 cells that are hypersensitive in children with asthma produce more IL-4, IL-5, and IL-13, which causes the synthesis of IgE, activation of eosinophils, and inflammation of the airways. On the other hand, Th1 and Th17 responses drive autoimmune diseases such as JIA and pediatric IBD, resulting in tissue damage and systemic inflammation via cytokines such as interferon gamma (IFN-γ) and IL-17 (25). Figure 4 demonstrates the complex and interdependent Th1, Th2, and Th17 immune responses, with the various cytokine responses produced by each subset of T cells and their contributions to pediatric inflammatory health. Th1 cells produce primarily IFN-γ and play central roles in defence against intracellular pathogens, but dysfunctional technologies responsible for excessive immune activation correlates towards autoimmune diseases (26). Different diseases are linked to abnormalities in the Th1, Th2, and Th17 subsets of T helper cells, each of which plays a unique function in immune responses. Th1 cells serve a crucial role in the defense against intracellular pathogens like viruses and are mostly involved in cellular immunity. They release pro-inflammatory cytokines, such as IFN-γ, which stimulate the immune response to intracellular infections by activating macrophages. Th2 cells, which secrete cytokines including interleukin-4 (IL-4), IL-5, and IL-13, are essential in allergic reactions and parasite infections. These cytokines play a key role in allergic illnesses such as asthma by promoting the generation of IgE, eosinophil activation, and airway inflammation. Chronic inflammation and autoimmune reactions are linked to Th17 cells (27). The health impact of these developmental processes of the adaptive immune response is profound when considering the developmental aspects of inflammatory disease pathogenesis. Newborns and infants possess a strong Th2 bias that slowly develops towards a balance in Th1/Th2 activity with a near-completeness of this process by school-aged years. This explains the changing epidemiology of allergic diseases, so-called diseases of the ‘modifiable immunome’, and the appearance of autoimmune illnesses within the autoimmunome, often occurring later in childhood. Since early life promotes diminished Treg function (i.e., they are ‘thirsty’) and imposes difficulty in dampening aberrant immune reactants, in adult life, the adaptive immune repertoire is ‘lazy’ and changes that are too hard to achieve. The implications of this concerning treatment applications are that early life interventions (e.g., allergen immunotherapy, probiotic administration) may help elicit long-lasting state change and tolerization, whereas adults typically require periodic reminders of intervention (“maintenance therapy”) (28).

Figure 4 The functions of Th1, Th2, and Th17 T helper cells in immunological responses are depicted in this image. Th1 cells activate macrophages by secreting IFN-γ, which protects against intracellular infections. By producing IL-4, IL-5, and IL-13, Th2 cells trigger allergic reactions that result in asthma by stimulating the synthesis of IgE and eosinophil activation. Th17 cells produce IL-17, which attracts neutrophils and plays a role in autoimmune conditions such as psoriasis and IBD. The image illustrates how different inflammatory diseases, such as autoimmune disorders (Th1/Th17) or allergies (Th2), can be brought on by imbalances in these subsets, whether Th1, Th2, or Th17 dominance. IBD, inflammatory bowel disease; IFN-γ, interferon gamma; IL, interleukin.

Oxidative stress and mitochondrial dysfunction

Oxidative stress and mitochondrial dysfunction are two of the main factors implicated in the pathogenesis of many pediatric inflammatory diseases, as they impact all forms of chronic inflammation, cause tissue damage, and contribute to the long-term effects seen in numerous pediatric conditions. Pathways related to the generation of reactive oxygen species (ROS) and impaired mitochondrial function are prominent in many neurodevelopmental and metabolic disorders in children and may even worsen the course of these disorders (29).

Immune cells, such as neutrophils, macrophages, and T cells, produce ROS in inflammatory states in response to infections, stress, or damage. Although ROS are essential for immune protection, excessive oxidative stress can increase ROS production, damaging proteins, lipids, and DNA, disrupt cells, and promote further inflammation (30).

Elevated ROS levels, which cause tissue damage, are frequently linked to persistent inflammation in juvenile illnesses. Excessive production of ROS in the lung damages airway epithelial cells, exacerbating airway hyperresponsiveness and potentially contributing to the disease’s chronicity (31). ROS generated by invading immune cells contribute to mucosal damage in IBD, hence sustaining chronic inflammation. The intestine’s chronic inflammatory state is sustained by elevated ROS levels, which start a loop of tissue destruction and an increased immune response (32). Oxidative stress and mitochondrial dysfunction extend ramifications that go beyond local damage, with relevant implications for neurodevelopment and metabolism. In children, prolonged exposure to oxidative stress can alter the developmental trajectory of the nervous system or exacerbate neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). ROS-related injuries to neuronal cells commonly affect synaptic function, neuronal growth, and plasticity, leading to abnormal brain development and cognitive disability. In neuroinflammatory conditions in children (e.g., pediatric multiple sclerosis, encephalitis), ROS-induced mitochondrial injury exacerbates the neuroinflammatory response, leading to neurological impairment (33).

Mitochondrial dysfunction is a common outcome of chronic oxidative stress. Mitochondria are responsible for bioenergetics, and when dysfunctional, they can disrupt metabolism, leading to energetic defects, cellular stress, and apoptosis. In pediatric metabolic disorders like obesity, diabetes, etc., mitochondria are frequently dysfunctional, and damage to mitochondria is commonly related to aberrant mitochondrial biogenesis and/or defective oxidative phosphorylation, which predisposes to insulin resistance and promotes adiposity (34). These mechanisms are illustrated in Figure 5, which shows how excessive ROS production drives tissue injury, inflammation, and chronic inflammation, and how mitochondrial dysfunction contributes to neurodevelopmental and metabolic disorders, as well as pediatric conditions such as multiple sclerosis and IBD.

Figure 5 Illustrated the role that ROS have in chronic inflammation and how they can cause injury to cellular components that drive further tissue damage/inflammation. They also illustrated mitochondrial dysfunction, including how dysfunctional (inadequate) mitochondrial function is impacting the neurodevelopmental and metabolic disorders commonly found in pediatric conditions related to pediatric MS and IBD. This pathway confirms the need for oxidative stress management in these diseases to avert long-term consequences. IBD, inflammatory bowel disease; MS, multiple sclerosis; ROS, reactive oxygen species.

Gut-immune-brain axis in pediatrics

The gut-immune-brain axis is a bidirectional communication network linking the GI system, the immune system, and the brain. The gut-immune-brain axis is critical for health and immune modulation; dysfunction or disruption of this axis has been associated with many pediatric disease processes. The gut microbiome, which is made up of trillions of microorganisms and is a changing and dynamic living system, resides in the gut at the centre of the gut-immune-brain axis, which impacts immune function and brain development, typically referred to in the literature as “gut-brain axis”. The disturbances and disruptions to the cross-talk of the microbiome through dysbiosis or other disturbances, disorders, and conditions, such as leaky gut, can produce neuroinflammatory outcomes that can impact both physical and mental health in children (35).

The development and operation of the immune system, especially in early childhood, are significantly influenced by the gut microbiota. The immunological system programming is triggered by microbial exposure, which promotes immunological tolerance and helps control immune responses. The intestinal epithelium, immune cells, and gut microbial populations interact to regulate cytokine production and the development of regulatory T cells (Tregs), which support tolerance and shield infants against allergies and autoimmune disorders. Furthermore, the microbiome plays a crucial role in controlling neuroinflammation and the blood-brain barrier (BBB). Treg differentiation and brain health are supported by SCFAs, which are generated by gut bacteria from dietary fiber. Early childhood microbiome disruptions can have a detrimental effect on brain health and immunological function, which can lead to illnesses like anxiety disorders, ADHD, and ASD (36,37).

An imbalance in the gut microbiome, in which pathogenic microbes outnumber helpful bacteria, is called dysbiosis. Numerous inflammatory and immune-related disorders, including autoimmune illnesses, asthma, and pediatric IBD, have been connected to it. Dysbiosis causes persistent inflammation and heightened vulnerability to autoimmune reactions in children by impairing the immune system’s ability to distinguish between harmful and benign stimuli. Although it may not be the main cause of neuroinflammation, the overactive immune response brought on by gut dysbiosis and leaky gut can affect brain development and impair social and cognitive performance (38-40).

Pathway-driven insights into specific pediatric inflammatory diseases

The pathogenesis of pediatric inflammatory diseases involves complex immune signaling pathways and how these pathways direct immune responses. Understanding pathways to provide more targeted, effective treatment options. Below, we focus on the mechanistic pathways that JIA, Pediatric IBD, Asthma and Atopy, and KD and MIS-C engage.

JIA: JAK/STAT signaling and IL-6 dominance

JIA is an autoimmune disease characterized by chronic inflammation of the joints. One of the main pathways involved in the pathogenesis of JIA is the JAK/STAT signaling pathway. Janus kinase (JAK) is a family of enzymes involved in signaling through cytokine receptors. Upon activation, the JAK/STAT signaling pathway leads to stimulation, phosphorylation, and activation of the signal transducer and activator of transcription (STAT) proteins, leading to the transcription of pro-inflammatory genes that regulate the differentiation, survival, and proliferation of immune cells (41). Specifically, IL-6 is a cytokine that signals via the JAK/STAT pathway and has a prominent role in the pathobiology of JIA. IL-6 stimulates the production of acute-phase proteins and is a conduit between the acute-phase response and the inflammatory cascade in the joints, resulting in the manifestations of pain, swelling, and stiffness. Suppressing IL-6 or blocking JAK activity with biologic therapies such as tocilizumab (anti-IL-6 receptor monoclonal antibody) and JAK inhibitors (e.g., tofacitinib) has been highly effective in treating JIA and controlling disease activity (42). The inflammatory network in JIA is further complicated by the use of the JAK/STAT signaling pathway by other cytokines, including IL-2, IL-4, IL-7, and IL-15, in addition to the crucial involvement of IL-6. For example, JAK1 and JAK3 play a critical role in autoimmune illnesses like JIA by activating STAT5 in response to IL-2, which promotes T cell survival and proliferation. Furthermore, it has been shown that STAT3, activated by IL-6, drives Th17 cell differentiation, which is linked to the pathophysiology of numerous autoimmune illnesses, including JIA. Th17 cells further spread the inflammatory cascade by releasing cytokines, including TNF-α and IL-17, which encourage inflammation and joint degeneration (43).

Additionally, recent studies have demonstrated that the deregulation of JAK/STAT signaling in JIA contributes to the persistence of joint inflammation by causing an imbalance in pro-inflammatory cytokines and immune cell activity. Compared to more general cytokine blocking, targeting JAK1/JAK3 or JAK2 with selective inhibitors provides a more focused approach to controlling JIA, possibly minimizing adverse effects. In clinical trials, these treatments have shown encouraging outcomes, especially for individuals who do not react to conventional biologics such as anti-TNF therapies (44). Figure 6 illustrates the JAK/STAT signaling cascade and highlights how JAK inhibitors, such as tofacitinib and baricitinib, block JAK1 and JAK3 activity to suppress pro-inflammatory cytokine transcription, thereby reducing chronic inflammation in pediatric diseases, including JIA and IBD.

Figure 6 Targeting the JAK/STAT pathway in pediatric inflammatory diseases. This figure shows the JAK/STAT signal transduction pathway, with JAK inhibitors, such as tofacitinib and baricitinib, blocking and antagonising JAK1 and JAK3, which activate pro-inflammatory cytokines. By blocking JAK enzymes, as depicted in this diagram, these inhibitors block cytokine signaling pathways. The critical diseases associated with the JAK inhibitors herein, specifically JIA and pediatric IBD, show how JAK pathway inhibition aids in reducing chronic inflammation and managing the disease, especially in pediatric patients. IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis.

Pediatric IBD: NOD2 mutations, microbiota imbalance, and NF-κB pathway

Pediatric IBD includes Crohn’s disease and ulcerative colitis and is characterized by chronic inflammation of the GI tract. A central mechanism underlying IBD is a mutation in the NOD2 gene. NOD2, an intracellular pattern recognition receptor, is involved in recognizing bacterial components such as muramyl dipeptide (MDP). When NOD2 is mutated, intestinal epithelial cells cannot respond appropriately to the microbiota, leading to dysregulated immune responses and an exaggerated inflammatory response. The dysbiosis (i.e., imbalance in the gut microbiota) worsens the inflammatory response. Dysbiosis can change the metabolite production, including SCFAs, which directly regulate intestinal homeostasis and immune tolerance (45).

The NF-κB pathway is crucial in the development and progression of IBD. NF-κB is a transcription factor that ultimately regulates the gene expression of pro-inflammatory cytokines, including TNF-α and IL-6, and other immune recruitment molecules. Importantly, chronic NF-κB activation in IBD leads to persistent inflammation and ultimately tissue damage in the intestinal mucosa. Thus, TNF-α (i.e., infliximab) and NF-kB therapies are routinely used in treatment to reduce inflammation and prevent IBD episodes or flare-ups (46).

Asthma and atopy: Th2 skewing and IL-4/IL-13 signaling

Asthma and atopy are associated with an exaggerated immune response to environmental allergens, resulting in varying degrees of chronic airway inflammation and hyperresponsiveness. In both cases, the pathogenesis is driven by an expansion of a Th2-skewed immune response. In asthma, this is characterized by an immune response that is essentially entirely mediated by Th2 cells, secretion of IL-4, IL-5, and IL-13 cytokine release. These cytokines are essential for the development of an allergic response by promoting the production of IgE, activation of eosinophils, and stimulating mucus secretion (47).

IL-4 and IL-13 are important in asthma because they stimulate B-cells to become IgE-producing plasma cells that lead to an allergic response to agents; They also activate airway epithelial cells that contribute to mucus production and airway remodelling. Therapies utilising monoclonal antibodies directed at blocking IL-4 and IL-13 signalling (e.g., dupilumab) have been demonstrated to reduce inflammation and respiratory distress, including acute exacerbations in severe asthma patients. In addition, eosinophilic inflammation has been associated with Th2 skewing seen in asthma. There are therapies available that block eosinophils (e.g., mepolizumab) that may be useful for reducing symptoms (48).

KD and MIS-C: endothelial inflammation, cytokine storm, and complement activation

KD and MIS-C both cause systemic inflammation, but they develop in different physiologic and epidemiologic contexts. KD is an acute vasculitis that most commonly develops in children <5 years of age, causing inflammation of blood vessels, including the coronary arteries. The pathophysiological mechanisms of KD involve endothelial inflammation, cytokine release, and immune activation, leading to the systemic vasculitis seen in the disease. Cytokines, including IL-1, TNF-α, and IL-6, are implicated in endothelial cell activation and the recruitment of immune cells in vascular inflammation (49).

In MIS-C, a hyperinflammatory syndrome important during the COVID-19 pandemic, a cytokine storm is central to its pathophysiology. Patients with MIS-C demonstrate elevated levels of pro-inflammatory cytokines, including IL-6, IL-1, and TNF-α, producing extensive tissue inflammation involving multiple organ systems, including the heart, lungs, and kidneys. Complement activation is also an important pathway for inflammation in KD and MIS-C, given its contribution to the inflammatory response and endothelial cell injury. Specific complement proteins (C3a and C5a) activate several immune cell types and induce the release of additional inflammatory mediators. In forms of KD and MIS-C, cytokine and complement activation have been targeted with therapies such as intravenous immunoglobulin (IVIG) and monoclonal antibodies to modify the inflammatory status of these patients, and in KD, attenuate significant complications (e.g., coronary artery aneurysms) (50).

Therapeutic approaches targeting pathways

Cytokine blockade

Cytokine blockade therapies are among the most promising and effective therapeutic modalities available for a variety of pediatric inflammatory diseases. By blocking specific cytokines in the inflammatory cascade, this medication alters the hyperactive immune response to this type of inflammatory injury, and importantly, it significantly limits the long-term sequela based on immune dysregulation. We will focus on IL-1 blockers (anakinra), IL-6 inhibitors (tocilizumab), and TNF inhibitors (adalimumab, infliximab), with specific emphasis on pediatric-specific outcomes and the prevalence of limitations (51). An important factor in comprehending inflammatory illnesses in children is the heterogeneity in cytokine profiles. For instance, asthma (Th2 dominance) and autoimmune disorders (Th1/Th17 predominance) exhibit distinct inflammatory patterns due to an imbalance between Th1/Th2/Th17. Nevertheless, the discovery of trustworthy biomarkers for targeted therapy is hampered by the reproducibility and uniformity of cytokine profiles (52).

IL-1 blockers (anakinra)

IL-1 is recognised as a principal pro-inflammatory cytokine responsible for several inflammatory diseases. IL-1 inhibitors, such as anakinra (a recombinant human IL-1 receptor antagonist), have shown promising clinical applications in these diseases. Anakinra binds to the IL-1 receptor to inhibit IL-1 pro-inflammatory responses on immune cells (53).

Anakinra has been effective in resolving joint inflammation, pain, and stiffness in pediatric JIA and has been shown to improve physical function and quality of life. In KD, anakinra can resolve systemic inflammation and avert systemic coronary artery issues, which, as a hallmark of the disease, is critical to prevent. Nevertheless, using anakinra in children has limitations, especially self-administration with subcutaneous injections, which may be a challenging task for a young child, and although daily, there are fewer injections than with corticosteroids. Further, into the long-term safety of IL-1 inhibition in children (54). The effectiveness and controllable safety profile of IL-1 blocking in juvenile inflammatory disorders are supported by recent data. Treatments like canakinumab and anakinra were shown to be significantly more efficacious than placebo in a 2024 network meta-analysis of IL-1-targeted biological therapies in JIA, with a favourable safety profile and no increase in major adverse events in children.

Long-term anakinra medication was linked to sustained illness management and a decreasing incidence of adverse events over time in a 2022 cohort study of children with systemic JIA (sJIA).

Additionally, a real-world study conducted in a sJIA cohort in 2024 showed that canakinumab permitted significant corticosteroid reduction or total withdrawal in the majority of patients, with most achieving complete or partial remission and no serious side effects reported (55).

Interleukin-6 (IL-6) inhibitors (tocilizumab)

IL-6 is another significant cytokine involved in the pathophysiology of several childhood inflammatory diseases. It initiates an acute-phase response and is an essential mediator of systemic inflammation. Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, is effective for sJIA and pediatric cytokine storm (56). In sJIA, it is effective for reducing fever, systemic inflammation, and preventing permanent joint damage. It has been effective for MIS-C related to COVID-19 in reversing the cytokine storm and local inflammatory phenomena associated with multi-organ, including the heart and lungs, inflammation. However, the evidence shows a significant challenge with tocilizumab is that it is an immunosuppressive drug—it presents a risk of increasing susceptibility to infections. Further, the long-term impacts of inhibition of IL-6 in childhood (growth and development) remain to be determined, and the use of tocilizumab requires routine monitoring.

TNF inhibitors (infliximab, adalimumab)

TNF-α is a critical cytokine in a variety of autoimmune as well as inflammatory diseases. TNF inhibitors, such as infliximab and adalimumab, have transformed treatment for IBD, JIA, and psoriasis. These biologics work by binding TNF-α, preventing TNF receptors on immune cells from binding, thereby reducing inflammation and tissue damage (57).

In pediatric IBD, infliximab has demonstrated considerable benefits in inducing and maintaining remission with better results in children with moderate to severe Crohn’s disease or ulcerative colitis. Likewise with JIA, TNF inhibitors have been associated with a reduction in joint inflammation and improvements in functional outcome. Second, the long-term costs of TNF inhibitors and the fact that they are given via intravenous infusion or subcutaneous injection further complicate access for some children admitted to a pediatric hospital (58).

Small-molecule pathway inhibitors

Cytokine blockade therapies have provided much utility in clinical care in children, although there are still concerns about complications. One of the issues with these therapies is safety for the long term in children, particularly with the development of a robust immune system. There may be a risk of infection, decreased growth, or malignancy from long-term use of these therapies. The differences in dose for many of the biologics and pharmacokinetic and pharmacodynamic properties of the agents would need to be addressed (59).

Cost of these inhibitors is still a significant limitation, even for those pharmacologically managed with these pharmacological agents, as they remain exceedingly difficult and, in some instances, only accessible to a few children with means and funding to cover the costs; and especially difficult in many low-resource and global health settings, despite their being pharmacological use for relative inflammation control. None of the cytokine inhibitors being used is curative; thus, long-term therapy is developed against a backdrop of implicit needs to combine agents (corticosteroids and immunosuppressants), treatment efficacy, and adverse effects testing and follow-up would be incorporated into the treatment (60).

JAK/STAT pathway modulators

JAK small-molecule inhibitors have emerged as an exciting new treatment modality in JIA and Pediatric IBD. Tofacitinib, baricitinib, and upadacitinib are examples of agents that inhibit JAK activity critical to immune signaling. Jak kinases and signal transducers and activators of transcription (STATs) transduce cytokine signaling through the Janus kinase/signal transducer and activator of transcription signaling pathway (JAK/STAT), which is a critical step in inflammatory regulation with many different cytokines (61).

In JIA, small-molecule JAK inhibitors are efficacious in children who have not responded to traditional therapies in decreasing joint inflammation, pain, and disability. Tofacitinib, in particular, functions as a JAK1 and JAK3 inhibitor; it inhibits cytokine-mediated signalling of cytokines such as IL-1 and IL-6, which have been shown to contribute to JIA inflammation. Limitations include limited long-term data on safety, infection risks, and dosing frequency (62). The idea that JAK inhibitors would be beneficial for children with IBD, in particular ulcerative colitis, is somewhat supported by early data from clinical trials. Tofacitinib has shown promise in inducing and maintaining remission by inhibiting IL-6, IL-12, and IL-23 signalling, which mediates gut inflammation. Early evidence suggests that JAK inhibitors could actually lead to a decrease in corticosteroid therapy and improve clinical outcomes, while long-term safety data would have to be obtained for pediatric indications (63). Long-term safety information remains limited, although JAK inhibitors such as tofacitinib and baricitinib have proven effective in treating pediatric inflammatory conditions, including JIA and IBD. Long-term follow-up studies are still needed to adequately address concerns about children’s growth, immune function, and infection risks. The effectiveness and relative safety of JAK inhibitors in treating inflammatory disorders in children are supported by recent data. For example, during the 2023 Baricitinib trial, children with JIA showed a significant improvement in disease activity compared with placebo. Similarly, real-world pediatric data on tofacitinib in children with arthropathy-complicated ulcerative colitis (a subtype of pediatric IBD) showed that many patients achieved clinical response and remission, with a significant percentage achieving steroid-free remission and endoscopic improvement over several weeks (64).

NLRP3 inflammasome inhibitors

Due to their involvement in tissue damage and chronic inflammation, NLRP3 inflammasomes and oxidative stress are being targeted in pediatric inflammatory disorders. Compared to broad cytokine inhibition, NLRP3 inhibitors, such as MCC950, provide more targeted therapy by reducing IL-1β production and blocking inflammasome activation. Although long-term safety and efficacy data in children remain limited, these inhibitors have demonstrated promise in conditions such as KD and JIA (65).

ROS are neutralized by antioxidants like vitamin E and N-acetylcysteine (NAC), which lowers oxidative stress and inflammation in diseases including asthma and IBD. Although these antioxidants shield tissues from oxidative damage, it is unclear how they will affect developing youngsters in the long run. Treatments for disorders with mitochondrial dysfunction, such as IBD and neuroinflammatory conditions, may benefit from mitochondrial-targeted medicines like MitoQ, which try to lower ROS at the mitochondrial level (66).

Microbiome-based interventions

Interventions targeting the microbiome are being developed as novel approaches for pediatric inflammatory diseases by modulating the gut microbiota, which is involved in immune regulation and inflammation. The goal of microbiome-based interventions is to restore a healthy balance of microbes to decrease symptoms and improve disease outcomes in conditions such as pediatric IBD, as well as asthma and neurodevelopmental disorders (67).

Recent pediatric investigations highlight the therapeutic potential of microbiota modification in inflammatory and allergic illnesses. Probiotics may directly affect mucosal immunity and barrier integrity in pediatric IBD, according to a 2023 study that found that giving the probiotic Pediococcus pentosaceus CECT8330 to juvenile colitis significantly reduced intestinal epithelial apoptosis, restored gut microbial balance, and changed macrophage polarization toward an anti-inflammatory phenotype.

Additionally, a 2025 meta-analysis of randomized controlled trials revealed that probiotic supplementation improved important pulmonary function metrics (e.g., FEV₁/FVC) and decreased the risk of acute exacerbation in children with asthma (risk ratio ≈ 0.38). This suggests that microbiome-targeted interventions may lessen airway inflammation and improve lung function in pediatric asthma (68).

Faecal microbiota transplantation (FMT)

FMT represents the transfer of faecal material from a healthy donor to a patient’s GI tract, with the intention of properly colonising a healthy microbiome. FMT has shown promise in IBD, especially for patients who have failed conventional treatment. FMT is intended to restore microbial diversity by re-establishing normal bacterial populations, restoring gut barrier function, and reducing intestinal inflammation. FMT has shown usability and donor-to-recipient safety as a potential treatment for Clostridium difficile infection, while its role in pediatric IBD is investigational. While there remain challenges regarding donor selection, intrinsic and/or long-term effectiveness, and transmission of infectious diseases or unwanted microbes, clinical trials continue to explore the potential benefits of FMT in children. FMT may in the future represent one potential therapeutic option for chronic GI inflammation treatment (69). The results of FMT for children with IBD are still, at best, inconsistent. While some research has demonstrated positive outcomes in reducing inflammation and restoring gut microbiota balance, other studies have yielded conflicting or unclear findings. Therefore, FMT cannot currently be regarded as a treatment for juvenile IBD that is universally effective, and more study is required to comprehend its potential and limitations fully (70).

Probiotics, postbiotics, and engineered microbial therapies

Probiotics are live beneficial bacteria that will restore the balance of gut microbes. Typical probiotics are used to treat or restore gut homeostasis. In pediatric IBD, asthma, and other inflammatory conditions, probiotics may decrease inflammation and improve gut health by modulating immune reactivity or enhancing the production of anti-inflammatory cytokines. Probiotic bacteria found in yoghurt or supplements commonly contain strains from the Lactobacillus and Bifidobacterium genera, which help enhance and maintain gut barrier integrity and mucosal immunity. While there is some evidence that probiotic supplementation may contribute to clinical improvements across a variety of pediatric conditions, the precise effects of probiotics in these diseases, as well as the reactions of different strains, are ongoing, and it is possible that certain strains will not have the desired therapeutic effect (71). Postbiotics consist of non-living microbial products (such as metabolites and cell wall components), and have garnered increased qualifications of their potential therapeutic effects. Postbiotics have the potential to modulate immune responses, reduce inflammation, and enhance gut barrier integrity, similar to probiotics but without the live bacterial component. Postbiotics may serve as a therapeutic option as a safer and more controlled approach, especially among vulnerable subsets of the pediatric population (72). These interactions are depicted in Figure 7, which highlights the dynamic relationship between the gut microbiota, immune system, and brain, showing how microbial imbalance (dysbiosis) contributes to pediatric IBD, asthma, and neuroinflammatory diseases, while also illustrating potential therapeutic strategies such as probiotics and FMT to restore microbial balance and immune regulation.

Figure 7 Demonstrates the dynamic relationship between the gut microbiota and immune system, emphasizing the gut-immune-brain axis and the role of microbial imbalance (dysbiosis) in mediating the effects of inflammation in disorders such as pediatric IBD, asthma, and neuroinflammatory disorders. This graphic also takes into consideration the possibility of microbiome-based therapies such as FMT and probiotics that may help restore microbial balance and modulate the immune response in pediatric patients. FMT, faecal microbiota transplantation; IBD, inflammatory bowel disease.

Emerging biologics and precision medicine

Emerging biologics and precision medicine are changing the game for pediatric inflammatory diseases by introducing therapies that are both targeted and personalized.

Nanomedicine and targeted drug delivery

Nanomedicine and gene-editing technologies, most notably CAR-Treg therapy, are arguably the most exciting approaches in this space. Nanomedicine is the practice of using nanoparticles to deliver a therapeutic agent to the site of inflammation, which means that drugs can be more stable, bioavailable, and targeted—the therapies are both faster and more effective, with the potential to reduce the risk of side effects associated with systemic therapies. In the context of pediatric diseases like IBD or JIA, nanomedicine can deliver biologic therapies (e.g., TNF inhibitors) directly to cells in the tissue, enabling the drug to act more effectively and decreasing off-target effects. The ability to deliver biologics in this manner will ultimately help children whose immune systems and bodies have not fully developed or matured in response to conventional therapies (73).

Gene-editing technologies (CRISPR-Cas9)

Gene-editing technologies like CRISPR-Cas9 offer new potential to make precise edits to immune cells, and possibly rectify immune dysfunction directly at the genetic source. The most exciting approaches in gene editing involve CAR-Treg therapy, in which regulatory T cells (Tregs) are engineered to improve their suppressive function and restore immune tolerance. CAR-Treg therapy has the potential to change the approach to the treatment of certain pediatric diseases (like pediatric IBD and JIA) characterized by destructive immune cells attacking the body’s own tissues. CAR-Treg therapy may enhance Treg function to prevent immune system overstimulation and uncontrolled chronic inflammation, which are hallmarks of WIL or inflammatory disorders (74). Figure 8 provides an overview of these emerging therapeutic strategies, including cytokine inhibitors (IL-1 and IL-6 blockers), JAK inhibitors, and gene-editing approaches, and illustrates how they interact with key inflammatory pathways to modulate immune responses in pediatric diseases such as IBD, asthma, and JIA.

Figure 8 Presents a schematic overview of new therapies in pediatric inflammatory diseases. The diagram provides an overview of cytokine blockers (e.g., IL-1 and IL-6 inhibitors), JAK inhibitors, and gene-editing therapies, and their relationships to key inflammatory pathways associated with pediatric inflammatory diseases, such as pediatric IBD, asthma, and JIA. The diagram describes how these therapies relate to each other mechanistically and suggests that these therapies may modulate immune responses, offering new and possibly improved treatment options for chronic pediatric inflammation. IBD, inflammatory bowel disease; IL, interleukin; JIA, juvenile idiopathic arthritis.

Pediatric-specific treatment considerations

While the strategies outlined above (cytokine inhibition, JAK inhibition, manipulation of the microbiome) hold great promise in treating paediatric inflammatory diseases, many of them are based on mechanisms of action initially derived from studies in adults, and their application to children requires further thought, at the very least because children are not simply smaller adults (75).

Age-appropriate dosing and pharmacokinetics

The issues of drug absorption, distribution, metabolism, and excretion vary between adults and children. The liver cytochrome P450 enzymes are less developed in neonates and infants, leading to reduced hepatic clearance. Renal tubular secretion is also less efficient in children, and the larger proportion of body water leads to an increased half-life and volume of distribution for hydrophilic drugs and the converse for lipophilic drugs. For the biologics, use of weight-based dosing is standard (e.g., infliximab, tocilizumab), but in those young patients receiving the drugs longer than three years, increasing evidence is becoming available that some children do need a larger weight-normalised dose, as they clear the drugs more quickly. Conversely, in JAK inhibitors (e.g., tofacitinib, baricitinib), great care is needed in whom to adjust the dose for based on age and weight, to say nothing of the state of renal function. A dosing protocol derived from adult studies cannot just be used in children who do not have dedicated studies aimed at this age group (76).

Long-term safety and growth considerations

Children treated with biologic or small-molecule therapies may face potential long-term risks not normally seen in adults. Chronic immunosuppression increases the susceptibility to the potential of greater risk for infections (e.g., vaccine-preventable infections), which should be planned for before the initiation of therapy. Growth suppression is possible; although the chronic inflammation itself causes growth impairment, some therapies, like chronic corticosteroids, delay growth further. Recently, IL-6 blockade with tocilizumab has been associated with an improvement in growth velocity in children with inflammatory systemic JIA, but its effect on bone mineral density and pubertal development must also be carefully monitored. The theoretical risk of malignancy with long-term JAK inhibitors is low but must be continually assessed, especially in children (77).

Impact on immune system development

Perhaps the most pediatric-specific of concerns lies in how immunomodulatory therapies will influence the developing immune system. Early-life immune programming sets down the foundations for long-term tolerance and memory. Intervening with biologic therapies at critical periods of development may have more than short-term implications beyond the therapy window. For example, in pediatric IBD, early anti-TNF therapy and the resetting of the immune set point may allow for drug-free remission after discontinuation—perhaps less commonly seen in adults. Conversely, prolonged immunosuppression during infancy may delay normal immune maturation, although little evidence for concern exists with currently commercialized pediatric biologics (78).

Transition from pediatric to adult care

Adult children with inflammatory disease need to transition their care from paediatrics to adult health settings. They are at risk of medication non-adherence, flares of their disease, and loss to follow-up during this transition. Treatment protocols differ between paediatric and adult practice, requiring careful reconciliation of medications. An adolescent may have different psychosocial considerations, dealing with issues of body image (e.g., corticosteroid induced weight gain), fertility (e.g., effects of immunosuppressants on reproductive health), and alcohol/drug interactions with their medications. Transition should be a structured plan involving coordination between the paediatric rheumatologist and adult rheumatologist/gastroenterologist (79).

Family-centered care and adherence

In adult patients, they are often successfully treating themselves, but this is not true in children, whose medications are administered by caregivers. Subcutaneous injections (anakinra, tocilizumab, adalimumab) require that caregivers be trained in the effective delivery of the medications, and can also leave the injection sites sore, making them difficult to take daily. Oral medications (JAKi) require that they be given every day reliably. Overall treatment burden (timely clinic visits, infusions, repetitive laboratory draws, etc.) is felt by the whole family, and can be a source of caregiver distress as well as impacting family income. Developmentally appropriate discussion of treatment intent and plans with the child, shared decision-making with families, and psychosocial support services are vital contributors to successful pediatric treatment programs (80).

Translational and clinical perspective

Current challenges in pediatric drug trials (ethics, long-term safety)

Pediatric drug studies face ethical and regulatory challenges that are unique to this work. Pediatric patients (especially newborns and young children) are considered ‘at-risk’ or potentially vulnerable subjects. In studying this population, research must consider their developmental needs, developmental assent (if appropriate), and their health and well-being. Considerations include weighing the potential benefits for the child against their risk of exposure to unknown, new therapies which have not yet been evaluated for safety and efficacy. The challenge of attaining informed consent from parents or guardians while also weighing the child’s assent (if appropriate) may pose significant challenges when recruiting children (81).

Significant concerns exist around the long-term safety of treatments in children. Children are still growing and are characterized by ongoing development of immune systems, metabolism, and organ function, which are continuing to develop, and there are uncertainties about how children will respond to medications. There is often a lack of understanding surrounding the long-term consequences of treatment on growth, development, and immune function. There are monitoring responsibilities around drug safety, and studies will need to monitor adverse effects that may occur over extended timeframes. Post-marketing surveillance is critical when studies may only involve short observational timeframes, to ensure drug safety after the drugs are formally accepted for use in children (82).

Biomarkers for patient stratification (cytokine signatures, microbiome profiles)

As treatments for pediatric inflammatory diseases become increasingly targeted, the ability to stratify patients based on characteristics of their diseases will become even more important for personalized medicine. Biomarkers, including cytokine signatures and microbiome signatures, are being utilised more regularly as a means of identifying subgroups of patients with similar treatable endpoints to identify who will benefit with maximal efficacy from particular therapies. Cytokine signatures may signify whether a patient with pediatric IBD or asthma has either a Th1, Th2, or Th17-driven immune system, helping to inform targeted approaches to use biologic therapies like TNF inhibitors or IL6 blockers. Likewise, microbiome profiling in pediatric IBD and KD may show gut ecosystem imbalances that are contributing to the disease pathogenesis, which may also aid in targeted treatment decisions for all therapies, including probiotics or FMT to restore a healthy microbiome (83).

The potential of omics (genomics, proteomics, metabolomics) for personalizing therapy

Through drug development using omics technologies (genomics, proteomics, and metabolomics), there is the potential to personalize treatment in the pediatric field.

Genomics is an examination of the genetic makeup of an individual based on their genes and is used in determining the variation specific to disease susceptibility and response to treatment, which generally presents itself as the individual’s genetic Signature. Health care providers of pediatric autoimmune disease JIA, for instance, can utilize genomics to examine the genomic profiles of JIA patients by assessing gene variants and polymorphisms that are used as markers to ascertain disease onset and disease progression while providing more directed care regardless of treatment (84).

Proteomics examines the total body protein complement, where studying proteins can advance understanding in determining how proteins can elaborate the disease process. Protein biomarkers, in areas of pediatric diseases such as pediatric osteoporosis or pediatric ulcerative colitis, can potentially anchor in distinct inflammatory pathways that may refine treatment (85).

• Metabolomics studies metabolites (small molecules resulting from metabolism) to provide directionality about the biological pathways involved in the process of disease. In pediatric asthma and pediatric IBD literature, metabolomics offers support in identifying and validating metabolic dysregulation that is associated with disease severity as part of the overall framework of a disease continuum, ultimately supporting more personalised treatment strategies and/or supporting improved overall therapeutic outcomes (86).

The collective potential of all three providing genomics, proteomics, and metabolomics allows clinicians to obtain the most visualized picture of their patient’s disease, from genetic susceptibility to how the body responds once treatment is commenced, thus providing personalization based on each child’s molecular profile, potentially improving effective treatment response and/or minimizing side effects associated with the chosen treatment.

Future directions

Forward progress in addressing pediatric inflammatory diseases will occur through precision medicine that integrates systems biology and immunomodulation with new technologies, such as AI-based pathway analysis. These elements will advance our understanding of disease processes and therapeutic effectiveness, particularly in children. However, access to effective therapies worldwide must also be addressed.

Pediatric immunology can greatly benefit from systems biology, which studies biological systems through the intricate interconnections among elements such as genetics, proteomics, metabolomics, and environmental factors. By using these, we can obtain a comprehensive understanding of how environmental exposures, immunological responses, and genetic predisposition interact to cause inflammatory illnesses in children. Even in the pre-symptomatic phase, the application of multi-omics techniques can provide important insights into the pathophysiology of the disease, enabling the identification of key treatment targets. This can also make it easier to apply these discoveries to personalized care, providing pediatric patients with specialized treatments. For instance, in diseases like JIA or IBD, these techniques can find predictive biomarkers for disease progression or response to treatment, enabling accurate and efficient therapies (87).

Preventive immunomodulation during crucial early-life windows is another potential approach in pediatric immunology. Infants and young children offer a unique opportunity for immunological training and programming, as their immune systems are highly flexible. Early introduction of therapies, such as probiotics, immunizations, or dietary changes, may assist the immune system in becoming tolerant to innocuous antigens, hence averting hyperactive immune responses in later life. This idea offers great potential for preventing autoimmune illnesses, allergies, and asthma by providing a preventive strategy rather than treating symptoms after the disease has appeared (88).

Exciting opportunities to discover new treatment pathways and repurpose existing medications for juvenile inflammatory illnesses are presented by combining artificial intelligence (AI) with biomedical research. AI systems can predict patient outcomes and provide deeper insights into disease causes by finding hidden patterns in massive datasets from genomic, proteomic, and clinical investigations. AI-driven pathway analysis may pinpoint key biological pathways underlying the onset and progression of inflammatory illnesses in children, enabling the development of tailored treatments. Additionally, AI could aid therapeutic repurposing by identifying approved pharmaceuticals for other disorders that could be effective for treating juvenile inflammatory diseases. This approach can save valuable time and resources, accelerating the development of new treatments. For example, AI models might examine preclinical and clinical data to identify off-target effects from existing medications that could help patients with diseases like IBD or juvenile arthritis, offering an affordable way to increase treatment options (89).

Significant gaps in access to care and therapies still exist worldwide, especially in low- and middle-income countries (LMICs), despite notable progress in the treatment of juvenile inflammatory disorders. Many children are unable to receive the same quality of care as those in higher-income settings due to obstacles such as inadequate infrastructure, a lack of qualified personnel, restricted access to biologic therapies, and a lack of pharmaceutical interest in these areas. Due to these disparities, children do not have the same access to precision medicine or biologic medications, which harms their health. We can significantly advance egalitarian pediatric care globally by expanding access to inexpensive drugs and ensuring the affordability of biologics (90,91).

Limitations

This review did not perform a quantitative systematic synthesis or meta-analysis, and therefore no pooled effect estimate can be provided. In addition, heterogeneity in study designs, patient populations, and outcome measures across the included literature makes direct comparison between studies difficult. Pediatric-specific clinical trial evidence for some emerging therapies, such as gene-editing approaches and NLRP3 inhibitors, remains limited. Furthermore, much of the currently available literature is derived from well-resourced pediatric populations in high-income countries, which may limit generalizability to low-resource settings. Finally, given the rapid pace of advances in this field, some recently published developments may not have been fully captured despite a comprehensive literature search.

Conclusions

Pediatric inflammatory diseases, including KD, asthma, pediatric IBD, and JIA, continue to impose a growing burden on children and healthcare systems worldwide. These conditions can significantly affect growth, development, and long-term quality of life, underscoring the need for therapies that address underlying disease mechanisms rather than symptoms alone. A pathway-centered understanding of pediatric inflammation—including cytokine signaling, inflammasome activation, immune ontogeny, and microbiome-host interactions—provides a strong foundation for more precise and effective therapeutic strategies. Emerging approaches such as cytokine blockade, JAK inhibitors, microbiome-based interventions, nanomedicine, and gene-editing technologies offer promising directions for improving outcomes in children. The integration of biomarkers, genomics, proteomics, and metabolomics into clinical decision-making may further support precision medicine tailored to each child’s immunological and molecular profile. Overall, a mechanism-driven, pediatric-focused therapeutic framework may help shift care from symptom control toward disease modification and improved lifelong health outcomes.

Acknowledgments

None.

Footnote

Peer Review File: Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0152/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0152/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. de Cevins C, Luka M, Smith N, et al. A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis. Med 2021;2:1072-92.e7.
2. Collier F, Chau C, Mansell T, et al. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children. Front Immunol 2021;12:830049. [Crossref] [PubMed]
3. Abdul S, Adeghe EP, Adegoke BO, et al. A review of the challenges and opportunities in implementing health informatics in rural healthcare settings. International Medical Science Research Journal 2024;4:606-31.
4. SanteGDBuonsensoDDe RoseCImmune profile of children with post-acute sequelae of SARS-CoV-2 infection (Long Covid).medRxiv; 2021. .10.1101/2021.05.07.21256539
5. Khoury M. Multisystem Inflammatory Syndrome in Children—Emerging Insights From Large Datasets. JAMA Netw Open 2025;8:e2456229. [Crossref] [PubMed]
6. Al-Beltagi M, Saeed NK, Mani PKC, et al. Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers. World J Gastroenterol 2025;31:111934. [Crossref] [PubMed]
7. El-Nefiawy N, Abdel-Hakim K, Kanayama N, et al. Dendritic cell differentiation and maturation in embryonic rat liver: immunohistochemistry and electron microscopy with reference to dendritic cell contacts. Anat Histol Embryol 2005;34:72-9. [Crossref] [PubMed]
8. Messerschmidt JL, Dempsey KE, Dillon KS, et al. Divergent Roles of Epithelium-Derived Alarmins in Notch Signaling-Deficient Skin. J Invest Dermatol 2020;140:2089-92. [Crossref] [PubMed]
9. Tsujioka Y, Nishimura G, Sugimoto H, et al. Imaging findings of juvenile idiopathic arthritis and autoinflammatory diseases in children. Jpn J Radiol 2023;41:1186-207. [Crossref] [PubMed]
10. Rehman H, Cheema HA, Alvi MA, et al. Assessment of quality of life among children with inflammatory bowel disease. Pakistan Armed Forces Medical Journal 2021;72:1698-702.
11. Aznaran-Torres R, Nombera-Lossio J, Arredondo-Nontol M, et al. Effects of Dupilumab in Children and Adolescents With Moderate-Severe Asthma: A Systematic Review of Clinical Trials. Pediatr Pulmonol 2025;60:e71138. [Crossref] [PubMed]
12. Miqdhaadh A, Imad HA, Fazeena A, et al. Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection in an Adult: A Case Report from the Maldives. Trop Med Infect Dis 2021;6:187. [Crossref] [PubMed]
13. Wang K, Yin J, Chen J, et al. Inhibition of inflammation by berberine: Molecular mechanism and network pharmacology analysis. Phytomedicine 2024;128:155258. [Crossref] [PubMed]
14. Vergani S, Yuan J. Developmental changes in the rules for B cell selection. Immunol Rev 2021;300:194-202. [Crossref] [PubMed]
15. Li S, Ling S, Wang D, et al. Modified lentiviral globin gene therapy for pediatric β(0)/β(0) transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial. Cell Stem Cell 2024;31:961-973.e8. [Crossref] [PubMed]
16. Bacorn M, Subramanian P, Levy S, et al. Faecal zonulin, calprotectin and the infant microbiome in early life. Clin Transl Med 2024;14:e1695. [Crossref] [PubMed]
17. Ercan Emreol H, Yildirim-Toruner C, Jelusic M, et al. New avenues in childhood vasculitis. Pediatr Rheumatol Online J 2025;23:97. [Crossref] [PubMed]
18. AbuBaha M, Aldwaik S, Abubaha B, et al. NLRP3 inflammasome expression in pediatric asthma: sputum-based insights, inflammatory mechanisms, and targeted therapeutic strategies. Allergy Asthma Clin Immunol 2025;22:2. [Crossref] [PubMed]
19. Holbrook JA, Jarosz-Griffiths HH, Caseley E, et al. Neurodegenerative Disease and the NLRP3 Inflammasome. Front Pharmacol 2021;12:643254. [Crossref] [PubMed]
20. Hamamoto Y, Ano S, Allard B, et al. Montelukast reduces inhaled chlorine triggered airway hyperresponsiveness and airway inflammation in the mouse. Br J Pharmacol 2017;174:3346-58. [Crossref] [PubMed]
21. Chalasani V, Parameswaran P, Cherico A, et al. SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra. Rheumatology (Oxford) 2022;61:e33-4. [Crossref] [PubMed]
22. Hart GW, Ramakrishnan P. Editorial: O-GlcNAcylation and the immune system. Front. Immunol 2024;15:1474042. [Crossref] [PubMed]
23. Cheng A, Holland SM. Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol 2024;24:161-77. [Crossref] [PubMed]
24. Prihantono P, Syamsu SA, Smaradhania N, et al. Application of scaevola taccada (gaertn.) roxb. reduce pro-inflammatory cytokines interleukin-1β in sprague dawley mice suffering from mastitis. Open Access Macedonian Journal of Medical Sciences 2020;8:423-7.
25. GrahamRSZachsDPCoteroVFirst-in-human demonstration of splenic ultrasound stimulation for non-invasively controlling inflammation.medRxiv; 2020. DOI: .
26. Li L, Yang X, Cai Z, et al. Aucubin regulates allergic airway inflammation in ovalbumin-induced allergic asthma in mice by controlling th2 cytokines. Pharmacognosy Magazine 2025;21:885-94.
27. Lee SH, Kim KW, Joo K, et al. Angiogenin ameliorates corneal opacity and neovascularization via regulating immune response in corneal fibroblasts. BMC Ophthalmol 2016;16:57. [Crossref] [PubMed]
28. Park SH, Ye BD, Yang SK. Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis? Gut Liver 2022;16:138-40. [Crossref] [PubMed]
29. Jiang R, Zhou H, Kong X, et al. Reactive Oxygen Species Modulate Th17/Treg Balance in Chlamydia psittaci Pneumonia via NLRP3/IL-1β/Caspase-1 Pathway Differentiation. Folia Biol (Praha) 2024;70:74-83. [Crossref] [PubMed]
30. Möller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Semin Immun 2026;27:391-408.
31. Licari A, Manti S, Castagnoli R, et al. Immunomodulation in Pediatric Asthma. Front. Pediatr. 2019;7:289. [Crossref] [PubMed]
32. Vemula S, Mylaram J, Yadala R, et al. Protective effects of naringenin on 5-fluorouracil induced pulmonary toxicity via modulation of NF-κB and Nrf2 pathway. Pakistan Veterinary Journal 2024;44:63-70.
33. Xing Y, Reznikov I, Ahmed AN, et al. Peripheral immune-inducer dendritic cells drive early-life allergic inflammation. Nature 2026;652:1308-17. [Crossref] [PubMed]
34. Han Y, Zhang M, Yu S, et al. Oxidative Stress in Pediatric Asthma: Sources, Mechanisms, and Therapeutic Potential of Antioxidants. Front. Biosci. (Landmark Ed) 2025;30:22688. [Crossref] [PubMed]
35. Ara A, Jan M, Sofi PA, et al. Reactive oxygen species, oxidative damage and their production, detection in common bean (phaseolus vulgaris l.) under water stress conditions. Advances in Plant Defense Mechanisms. IntechOpen; 2022. Doi: 10.5772/intechopen.106164.
36. Zuo X, Guo X, Gu Y, et al. A novel catalase nanogels for effective treatment of neutrophilic asthma. Advanced Functional Materials 2024;34:2316496.
37. Luo H, Birjandi AA, Ren F, et al. Advances in oral mesenchymal stem cell-derived extracellular vesicles in health and disease. Genes Dis 2023;11:346-57.
38. Salles GR, Giraldi LA, da Silva NS, et al. 2D and 3D Models of Alzheimer's Disease: Investigating Neuron-like Cells in Oxidative Environments. ACS Omega 2025;10:27501-14. [Crossref] [PubMed]
39. Wang Z, Li F, Ni P, et al. Age-related changes in adipose tissue metabolomics and inflammation, cardiolipin metabolism, and ferroptosis markers in female aged rat model. Biochemical and Biophysical Research Communications 2023;671:292-300.
40. Cho J, Park YJ, Gonzales-Portillo B, et al. Gut dysbiosis in stroke and its implications on Alzheimer's disease-like cognitive dysfunction. CNS Neurosci Ther 2021;27:505-14. [Crossref] [PubMed]
41. Ning X, Lei Z, Rui B, et al. Gut microbiota promotes immune tolerance by regulating rorγt+ treg cells in food allergy. Advanced Gut Microbiome Research 2022;2022:8529578.
42. Sadaka Y, Freedman J, Ashkenazi S, et al. The Effect of Antibiotic Treatment of Early Childhood Shigellosis on Long-Term Prevalence of Attention Deficit/Hyperactivity Disorder. Children (Basel) 2021;8:880. [Crossref] [PubMed]
43. Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory Bowel Diseases and Gut Microbiota. Int J Mol Sci 2023;24:3817. [Crossref] [PubMed]
44. Sagheer S, Rasheed MS, Ashraf F, et al. Enhancing rheumatoid arthritis treatment by subcutaneous methotrexate injections and anti-IL-2 antibody synthesis. International Journal of Agriculture and Biosciences 2024;13:101-11.
45. Warren A, Nyavor Y, Zarabian N, et al. The microbiota-gut-brain-immune interface in the pathogenesis of neuroinflammatory diseases: a narrative review of the emerging literature. Front Immunol 2024;15:1365673. [Crossref] [PubMed]
46. Ali SS, Li Q, Agrawal PB. Implementation of multi-omics in diagnosis of pediatric rare diseases. Pediatr Res 2025;97:1337-44. [Crossref] [PubMed]
47. Chen J, Chen F, Peng S, et al. Effects of Artemisia argyi Powder on Egg Quality, Antioxidant Capacity, and Intestinal Development of Roman Laying Hens. Front Physiol 2022;13:902568. [Crossref] [PubMed]
48. Sekine Y, Kikkawa K, Witthuhn BA, et al. A novel intramolecular negative regulation of mouse Jak3 activity by tyrosine 820. Int Immunol 2022;34:303-12. [Crossref] [PubMed]
49. Bagri NK, Chew C, Ramanan AV. Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward. Pediatr Drugs 2023;25:635-47.
50. Williams L, Alshehri A, Robichaud B, et al. The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia. Int J Mol Sci 2020;21:5252. [Crossref] [PubMed]
51. Tosi M, Montanari C, Bona F, et al. Dietary Inflammatory Potential in Pediatric Diseases: A Narrative Review. Nutrients 2023;15:5095. [Crossref] [PubMed]
52. Patel A. Diminished Dendritic Cell Interleukin 10 Production in Atopic Children. Annals of Allergy, Asthma Immunology, Elsevier BV, 2004.
53. Ridolo E, Pucciarini F, Nizi MC, et al. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother 2020;16:2349-56. [Crossref] [PubMed]
54. Cavallo A, Camera E, Maiellaro M, et al. Effects of Th1/Th17 and Th2 cytokines on lipid metabolism in differentiated keratinocytes. Front Physiol 2025;16:1387128. [Crossref] [PubMed]
55. Okada S, Hashimoto S, Miyake A, et al. Kawasaki Disease Following Severe Sunburn Injury. Front Pediatr 2020;8:6. [Crossref] [PubMed]
56. Lee MS, Liu YC, Tsai CC, et al. Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki Disease. Front Pediatr 2021;9:640118. [Crossref] [PubMed]
57. NarainSStefanovDGChauASComparative Survival Analysis of Immunomodulatory Therapy for COVID-19 ‘Cytokine Storm’: A Retrospective Observational Cohort Study.medRxiv; 2020. DOI: .
58. Dezfouli KA, Darban M, Hemmati M, et al. A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma. Drug Res (Stuttg) 2025;75:162-8. [Crossref] [PubMed]
59. Della Paolera S, Valencic E, Piscianz E, et al. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic. Front Pediatr 2020;8:624248. [Crossref] [PubMed]
60. Zhang W, Chen Y, Yao Z, et al. Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals (Basel) 2025;18:114. [Crossref] [PubMed]
61. Simon H Junior, Sakano TMS, Rodrigues RM, et al. Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view. J Pediatr (Rio J) 2021;97:140-59. [Crossref] [PubMed]
62. Nada DW, Moghazy A, Allam AE, et al. Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study. Front Med (Lausanne) 2021;8:665028. [Crossref] [PubMed]
63. Murakami M, Tomiita M, Nishimoto N. Tocilizumab in the treatment of systemic juvenile idiopathic arthritis. Open Access Rheumatol 2012;4:71-9. [Crossref] [PubMed]
64. Wang H, Hu Y, Chen F, et al. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. BMC Pregnancy Childbirth 2022;22:854. [Crossref] [PubMed]
65. Yin QL, Liu YQ, Zhang HM, et al. Progress of biological agents and CAR cell therapy in the treatment of common autoimmune diseases in children. Front. Pediatr 2026;14:1742663. [Crossref] [PubMed]
66. Zhang B. CRISPR/Cas9: A Robust Genome-Editing Tool with Versatile Functions and Endless Application. International Journal of Molecular Sciences 2020;21:5111.
67. Peng S, Xu C, He Q, et al. Fucoidan alleviates intestine damage in mice induced by LPS via regulation of microbiota. Pak Vet J 2024;44:517-25.
68. Goldman A, Raschi E, Druyan A, et al. Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterol J 2025;13:566-75. [Crossref] [PubMed]
69. Kostik MM, Raupov RK, Suspitsin EN, et al. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience. Front. Pediatr. 2022;10:820586. [Crossref] [PubMed]
70. Yao Y, Yang Z, Xie T, et al. Multi-Omics Analyses of the Gut Microbiota and Metabolism in Cats with Different Body Conditions and the Effects of Fecal Microbiota Transplantation. Veterinary Sciences 2026;13:436.
71. Magnoli AP, Parada J, Luna Marfa J, et al. Impact of probiotic saccharomyces cerevisiae var. boulardii rc009 alone and in combination with a phytase in broiler chickens fed with antibiotic-free diets. Agrobiol Rec 2025;16:1-10.
72. Suthar V. Research review on genetic engineering of probiotics in biotechnology. Med Plant Lett 2025;1:54-69.
73. Iqbal T, Altaf S, Salma U, et al. Cell membrane coated polymeric nanocarriers: a novel drug delivery approach for the targeted therapy of rheumatoid arthritis. Agrobiol Rec 2024;15:91-102.
74. Abdolshahi A, Bagheri B, Darban M, et al. A randomized, controlled study evaluating the effects of saccharomyces boulardii in adult patients with asthma. Drug Res (Stuttg) 2025;75:162-8.
75. Kushnareva MV, Yurieva EA, Dlin VV, et al. ANTIOXIDANTS IN PEDIATRICS. (REVIEW). Int. J. Mod. Pharm. Res 2023;7:1-8.
76. Wu X, Li P, Wang W, et al. The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation. Nutrients 2023;15:3340. [Crossref] [PubMed]
77. Aghamohammad S, Sepehr A, Miri ST, et al. The potential role of Bifidobacterium spp. as a preventive and therapeutic agent in controlling inflammation via affecting inflammatory signalling pathways. Lett Appl Microbiol 2022;75:1254-63.
78. Zakuan NM, Phia W, Yazan LS. Exploring the antimicrobial properties and potential of lactobacillus plantarum postbiotic engineering k-016. Int J Sci Res Manag 2024;12:1064-8. (IJSRM).
79. Funk RS, Shakhnovich V, Cho YK, et al. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Pediatr Rheumatol Online J. 2021;19:62. [Crossref] [PubMed]
80. Yu L, Fu Y, Miao R, et al. Regulatory t cells and their derived cell pharmaceuticals as emerging therapeutics against autoimmune diseases. Adv Funct Mater 2024;34:2405133.
81. Afolabi MO, Kelly LE. Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials. J Med Ethics 2022;48:825-31. [Crossref] [PubMed]
82. Lee E, Sol IS, Kim JD, et al. Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis. Sci Rep 2021;11:24287. [Crossref] [PubMed]
83. Hayajneh FMFA, Ahmed Z, Khatoon A, et al. Epidemiological investigations of mycoplasma bovis-associated mastitis in dairy animals along with analysis of interleukin-6 (IL-6) as a potential diagnostic marker. Int J Vet Sci 2024;13:120-6.
84. Hinks A, Eyre S, Ke X, et al. Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:1049-53. [Crossref] [PubMed]
85. Kajana X, Spinelli S, Garbarino A, et al. Identification of Central Nervous System Oncologic Disease Biomarkers in EVs from Cerebrospinal Fluid (CSF) of Pediatric Patients: A Pilot Neuro-Proteomic Study. Biomolecules 2023;13:1730. [Crossref] [PubMed]
86. Dong R, Meng X, Hu H, et al. Integrating gut microbiota and metabolomics in pediatric inflammatory bowel disease: insights into pathogenesis and potential role of precision medicine. Eur J Med Res 2026;31:63.
87. Landrigan, Philip J., and Ruth A. Etzel, 'Children’s Environmental Health: A New Branch of Pediatrics', in Ruth A. Etzel, and Philip J. Landrigan (eds), Textbook of Children's Environmental Health, 2nd edn (New York, 2024; online edn, Oxford Academic, 18 July 2024), https://doi.org/10.1093/oso/9780197662526.003.0001, accessed 23 May 2026.
88. Eskander A, Rady H, Balah M, et al. Evaluating transforming growth factor-B and interleukin-6 as a prognostic markers in pediatric critically ill septic patients. Egypt Pediatric Association Gaz 2025;73:54.
89. Williams RT, Anderson PL. Artificial intelligence-enabled drug repurposing for pediatric inflammatory diseases: current status and future directions. Trends Pharmacol Sci 2024;45:512-8.
90. Al-Khalaifah H, Rahman MH, Al-Surrayai T, et al. A One-Health Perspective of Antimicrobial Resistance (AMR): Human, Animals and Environmental Health. Life 2025;15:1598.
91. Khan S, Ferdoos S, Farooq J, et al. Processing wheat for gut health: enzymatic and fermentation approaches with glycemic implications. Med Plant Lett 2026;2:38-57.